The U.S. inflammatory bowel disease treatment market size was exhibited at USD 11.85 billion in 2023 and is projected to hit around USD 15.47 billion by 2033, growing at a CAGR of 2.7% during the forecast period 2024 to 2033.
Report Coverage | Details |
Market Size in 2024 | USD 12.17 Billion |
Market Size by 2033 | USD 15.47 Billion |
Growth Rate From 2024 to 2033 | CAGR of 2.7% |
Base Year | 2023 |
Forecast Period | 2024-2033 |
Segments Covered | Type, Drug Class, Route of Administration, Distribution Channel, Region |
Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
Regional Scope | U.S. |
Key Companies Profiled | Biogen; Novartis AG; Eli Lilly and Company; UCB S.A.; Celltrion Inc.; Merck & Co., Inc.; Johnson & Johnson Services, Inc. |
The global incidence of inflammatory bowel diseases (IBD), which includes Crohn's disease and ulcerative colitis, is increasing, primarily due to changes in lifestyle, dietary habits, and environmental factors. According to an article published in 2023, inflammatory bowel disease is a relatively common chronic condition affecting >0.7% of Americans and is most prevalent in the Northeastern region. This growing patient population needs advanced treatment options, driving the market growth.
Major pharmaceutical companies invest in research and development for IBD treatments, acquiring smaller companies or forming strategic partnerships to expand their product portfolios. In October 2023, Sanofi and Teva collaborated to deliver therapy for inflammatory bowel diseases (TEV’574, currently in the 2b Phase of clinical trials for treating ulcerative colitis and Crohn's Disease). This collaboration supported Sanofi’s immunology strategy of exploring novel mechanisms of action for these diseases.
According to the Gastroenterology and Endoscopy news, the prevalence of inflammatory bowel diseases in 2023 in the U.S. is among the highest in the world. Governments and private insurers worldwide are recognizing the importance of managing these diseases effectively to reduce long-term healthcare costs and improve the quality of life of patients. This has led to increased healthcare spending on inflammatory bowel disease treatments, further driving market growth.
Crohn’s disease dominated the market in 2023 with a revenue share of 62.30%. Crohn's disease requires more treatment options and advancements due to its chronic inflammatory nature that affects the gastrointestinal tract, causing symptoms such as abdominal pain, diarrhea, weight loss, and fatigue. Crohn's disease often has periods of remission followed by relapses, making it difficult to manage in the long term. More effective treatments are needed to help patients maintain remission and improve their overall health. In October 2023, Eli Lilly and Company announced that mirikizumab (an investigational interleukin-23p19 antagonist) achieves safety and efficacy in treating adults with Crohn's disease. Crohn's disease has an increased prevalence due to its variability in response to treatment, limited understanding of the disease, recurrence and remission challenges, potential complications, and the impact on patients' quality of life.
The ulcerative colitis segment is anticipated to register the fastest CAGR over the forecast period. Untreated or poorly managed ulcerative colitis can lead to complications such as severe bleeding, increased risk of colon cancer, and life-threatening inflammation known as toxic megacolon. The complex and unpredictable nature of ulcerative colitis, along with the need for ongoing management to maintain quality of life and prevent complications, makes it a condition that requires more extensive treatment.
In terms of drug class, the TNF inhibitors segment held the largest market revenue share in 2023. Tumor Necrosis Factor (TNF) inhibitors are in high demand for treating inflammatory bowel diseases (IBD) due to their effectiveness in managing the symptoms and reducing inflammation. Inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis, are chronic conditions characterized by inflammation in the gastrointestinal tract. This inflammation can lead to abdominal pain, diarrhea, weight loss, and other complications. The demand for TNF inhibitors in this treatment is high due to their proven efficacy in managing symptoms, inducing and maintaining remission, and improving patients' overall quality of life.
The JAK inhibitors segment is anticipated to register the fastest CAGR during the forecast period. The segment's expansion is anticipated due to the growing endorsement of innovative JAK inhibitors and potent pipeline medications. According to the Gastroenterology & Endoscopy news, in 2022, the FDA approved Rinvoq for treating ulcerative colitis. This increase in the number of regulatory approvals, in turn, leads to market growth.
The injectable segment dominated the market in 2023 in terms of revenue share 90.0%. Injectable medications, such as biologics and biosimilars, are designed to target specific proteins or cells involved in the inflammatory process of inflammatory bowel disease. This targeted approach allows for more efficient and effective treatment than traditional oral or topical medications, which may have broader side effects. Injectables can provide systemic treatment; they circulate throughout the body and reach affected areas more effectively than local treatments, which may only address the symptoms at the application site.
The oral segment is projected to grow at the fastest CAGR over the forecast period. Oral medications can be easily swallowed and taken with water, making them more convenient for patients than other administration routes, such as injections or infusions. This is particularly important for long-term management of chronic conditions such as IBD. Oral medications can be combined with other treatments, such as biologics or immunosuppressants, to enhance their effectiveness in managing these diseases. This approach can help improve treatment outcomes and reduce the risk of complications. In October 2023, the U.S. FDA approved Pfizer’s VELSIPITY, an oral treatment for adults with active ulcerative colitis (UC).
The hospital pharmacies segment held the largest revenue share in 2023. The inflammatory bowel diseases, including Crohn's disease and ulcerative colitis, require a complex and tailored treatment approach. Patients often need a combination of medications, including immunosuppressants, biologics, and anti-inflammatory drugs. Hospital pharmacies have the expertise and resources to manage such intricate medication regimens.
The online pharmacies segment is expected to register the fastest CAGR during the forecast period. Online pharmacies offer a convenient way for patients to access medications without leaving their homes. This is particularly beneficial for individuals with IBD, who may experience periods of increased symptoms or flare-ups, making it difficult for them to visit a physical pharmacy.
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the U.S. inflammatory bowel disease treatment market
Type
Drug Class
Route of Administration
Distribution Channel
Regional
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Type
1.2.2. Drug Class
1.2.3. Route of Administration
1.2.4. Distribution Channel
1.2.5. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Volume price analysis (Model 2)
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Type
2.2.2. Drug Class
2.2.3. Route of Administration
2.2.4. Distribution Channel
2.3. Competitive Insights
Chapter 3. U.S. Inflammatory Bowel Disease Treatment Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.2. Market restraint analysis
3.3. U.S. Inflammatory Bowel Disease Treatment Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
Chapter 4. U.S. Inflammatory Bowel Disease Treatment Market: Type Estimates & Trend Analysis
4.1. Type Market Share, 2024 & 2033
4.2. Segment Dashboard
4.3. U.S. Inflammatory Bowel Disease Treatment Market by Type Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the Following
4.4.1. Crohn's Disease
4.4.1.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
4.4.2. Ulcerative Colitis
4.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
Chapter 5. U.S. Inflammatory Bowel Disease Treatment Market: Drug Class Estimates & Trend Analysis
5.1. Drug Class Market Share, 2024 & 2033
5.2. Segment Dashboard
5.3. U.S. Inflammatory Bowel Disease Treatment Market by Drug Class Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the Following
5.4.1. Aminosalicylates
5.4.1.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
5.4.2. Corticosteroids
5.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
5.4.3. TNF Inhibitors
5.4.3.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
5.4.4. IL Inhibitors
5.4.4.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
5.4.5. Anti-integrin
5.4.5.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
5.4.6. JAK Inhibitors
5.4.6.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
5.4.7. Others
5.4.7.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
Chapter 6. U.S. Inflammatory Bowel Disease Treatment Market: Route of Administration Estimates & Trend Analysis
6.1. Route of Administration Market Share, 2024 & 2033
6.2. Segment Dashboard
6.3. U.S. Inflammatory Bowel Disease Treatment Market by Route of Administration Outlook
6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the Following
6.4.1. Oral
6.4.1.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
6.4.2. Injectable
6.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
Chapter 7. U.S. Inflammatory Bowel Disease Treatment Market: Distribution Channel Estimates & Trend Analysis
7.1. Distribution Channel Market Share, 2024 & 2033
7.2. Segment Dashboard
7.3. U.S. Inflammatory Bowel Disease Treatment Market by Distribution Channel Outlook
7.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the Following
7.4.1. Hospital Pharmacy
7.4.1.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
7.4.2. Retail Pharmacy
7.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
7.4.3. Online Pharmacy
7.4.3.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
Chapter 8. U.S. Inflammatory Bowel Disease Treatment Market: Region Estimates & Trend Analysis
8.1. Regional Market Share, 2024 & 2033
8.2. U.S. Inflammatory Bowel Disease Treatment Market by Region Outlook
8.3. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the Following
8.3.1. West
8.3.1.1. Market estimates and forecasts 2021 to 2033
8.3.2. Midwest
8.3.2.1. Market estimates and forecasts 2021 to 2033
8.3.3. Northeast
8.3.3.1. Market estimates and forecasts 2021 to 2033
8.3.4. Southwest
8.3.4.1. Market estimates and forecasts 2021 to 2033
8.3.5. Southeast
8.3.5.1. Market estimates and forecasts 2021 to 2033
Chapter 9. Competitive Landscape
9.1. Recent Developments & Impact Analysis, By Key Market Participants
9.2. Company/Competition Categorization
9.3. Vendor Landscape
9.3.1. List of key distributors and channel partners
9.3.2. Key customers
9.3.3. Key company heat map analysis, 2024
9.4. Company Profiles
9.4.1. Biogen
9.4.1.1. Company overview
9.4.1.2. Financial performance
9.4.1.3. Product benchmarking
9.4.1.4. Strategic initiatives
9.4.2. Novartis AG
9.4.2.1. Company overview
9.4.2.2. Financial performance
9.4.2.3. Product benchmarking
9.4.2.4. Strategic initiatives
9.4.3. Eli Lilly & Company
9.4.3.1. Company overview
9.4.3.2. Financial performance
9.4.3.3. Product benchmarking
9.4.3.4. Strategic initiatives
9.4.4. UCB S.A.
9.4.4.1. Company overview
9.4.4.2. Financial performance
9.4.4.3. Product benchmarking
9.4.4.4. Strategic initiatives
9.4.5. Celltrion Inc.
9.4.5.1. Company overview
9.4.5.2. Financial performance
9.4.5.3. Product benchmarking
9.4.5.4. Strategic initiatives
9.4.6. Merck & Co., Inc.
9.4.6.1. Company overview
9.4.6.2. Financial performance
9.4.6.3. Product benchmarking
9.4.6.4. Strategic initiatives
9.4.7. Johnson & Johnson Services, Inc.
9.4.7.1. Company overview
9.4.7.2. Financial performance
9.4.7.3. Product benchmarking
9.4.7.4. Strategic initiatives